Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Jin He, M.D., Ph.D., is a professor of surgery at the Johns Hopkins University School of Medicine and is the Division Chief of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology. Dr. He specializes in diseases and tumors of the pancreas, liver, bile duct, and gallbladder. He performs open as well as minimally invasive (robotic and laparoscopic) surgery, including the Whipple procedure. Dr. He received his medical degree from Beijing Medical University and a Ph.D. in oncology from Fudan University Shanghai Medical College. He completed the Halsted general surgery residency training at Johns Hopkins, followed by an ACGME accredited fellowship in complex general surgical oncology at Johns Hopkins. Dr. He is the John Cameron Professor of Alimentary Tract Diseases. Dr. He’s research focuses on personalized treatment through stratifying pancreatic tumors on their genetic features. He holds several patents in anti-cancer vascular targeting agents and has published extensively in peer-reviewed journals and lectured internationally. He serves on several national committees, including the NCCN panel on neuroendocrine tumors and the Alliance for Clinical Trials in Oncology. Dr. He is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Narang is an Assistant Professor in the Johns Hopkins Department of Radiation Oncology & Molecular Sciences. A former chief resident in the department, Dr. Narang now specializes in radiation treatment for gastrointestinal malignancies, including pancreatic cancer, colorectal cancer, hepatobiliary malignancies, and gastric cancer. Dr. Narang has an interest in expanding multi-disciplinary care for patients with gastrointestinal malignancies. Make A Gift. Dr. Narang is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatoblastoma, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Dr. Ross C. Donehower is an oncologist in the Baltimore area, caring for patients with gastrointestinal cancers. He was part of the team that developed premedications that allowed paclitaxel — a chemotherapy medication now used to treat several types of cancers — to be safely given to patients. The Virginia and D.K. Ludwig Professor in Clinical Investigation of Cancer, he serves as the director of the Hematology & Medical Oncology Fellowship Program and director of the Division of Medical Oncology at the Johns Hopkins School of Medicine. Dr. Donehower received his undergraduate degree from Hamline University and earned his M.D. from the University of Minnesota. He completed his residency at The Johns Hopkins Hospital. Dr. Donehower joined the Johns Hopkins faculty in 1980. Prior to joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate of the medicine branch and clinical pharmacology branch at the National Cancer Institute. His research interests include gastrointestinal cancers, new anticancer drug development and pharmacology. Dr. Donehower serves on the editorial boards of numerous scholarly journals, including the International Journal of Oncology. He has been recognized by the American Society of Clinical Oncology with a 2017 Excellence in Teaching Award. He is a member of several professional organizations, including the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Donehower is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Dr. Youngjee Choi is an assistant professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include internal medicine, cancer survivorship, and primary care. Dr. Choi completed her undergraduate degrees in psychology and philosophy-neuroscience-psychology at Washington University in St. Louis. She received her medical degree from Washington University School of Medicine and completed internship and residency at Barnes-Jewish Hospital/Washington University School of Medicine. Dr. Choi was selected as a chief resident and was a faculty member at Washington University School of Medicine before joining the Division of General Internal Medicine at Johns Hopkins in 2015. She is an active member of the Society of General Internal Medicine. Her academic and clinical interests include medical education, high value care, and improving the delivery of care for cancer survivors. She is currently the director of the Johns Hopkins Primary Care for Cancer Survivors program. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Choi is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Type 2 Diabetes (T2D), Osteoporosis, Postmenopausal Osteoporosis, Maturity Onset Diabetes of the Young, and Colonoscopy.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist in Lutherville, Maryland. Dr. Kalra has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Debashish Bose is a Surgical Oncologist and a General Surgeon in Baltimore, Maryland. Dr. Bose is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Pseudocyst, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bose is currently accepting new patients.

Ana De Jesus is an Oncologist in Baltimore, Maryland. Dr. De Jesus is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Cameron has had a long and distinguished career in alimentary tract diseases and specifically in pancreatic cancer. He has won worldwide acclaim for mastering the Whipple procedure. At the beginning of his career, the mortality rate from the Whipple procedure was nearly 30 percent. He has worked to lower that to 1 percent to 2 percent at Johns Hopkins. He has operated on more patients with pancreatic cancer and done more Whipple resections than any other surgeon in the world. In addition to maintaining a busy practice that focuses mainly on pancreatic surgery, he has been a leader in the surgical profession, serving as president of the American College of Surgeons, Society for Surgery of the Alimentary Tract, Southern Surgical Association, Society of Clinical Surgery, Society of Surgical Chairmen, Halsted Society and American Surgical Association. He served as chief of surgery for The Johns Hopkins Hospital for nineteen years. Dr. Cameron obtained his undergraduate degree from Harvard University in 1958, and his medical degree from The Johns Hopkins University School of Medicine in 1962. All of his training in General and Thoracic Surgery was obtained at The Johns Hopkins Hospital. Dr. Cameron is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.

Richard Burkhart, M.D., is an Associate Professor of Surgery at The Johns Hopkins Hospital with a focus on complex minimally-invasive surgery and research for cancers of the pancreas, liver and bile ducts. Dr. Burkhart received his medical degree from Boston University and completed his surgical residency and research fellowships at the Thomas Jefferson University Hospital in Philadelphia and the Cold Spring Harbor Laboratories. He is a member of several professional organizations, including the American Association of Cancer Research, the American College of Surgeons, the Society of Surgery for the Alimentary Tract, the Pancreas Club, and the Society of Surgical Oncology. Outside the operating room, Dr. Burkhart heads a multidisciplinary laboratory team dedicated to bringing next-generation precision medicine approaches into the routine clinical care of patients that we serve. He has a particular research interest in using personalized models of pancreas cancer, made from tumor during and immediately after surgical resection, to select the best chemotherapy for each patient to support long-term survival and improve rates of disease cure. The laboratory team, funded in part by the National Institutes of Health, the National Cancer Institute, the Lustgarten Foundation and Stand Up to Cancer, is also thankful to the many patients who have supported the work through philanthropic gift. Dr. Burkhart is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy.

William Burns, M.D., is an assistant professor of surgery at the Johns Hopkins University School of Medicine and a surgeon within the Division of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology at The Johns Hopkins Hospital. Prior to joining the faculty at Johns Hopkins, Dr. Burns served as an assistant professor of surgery at the University of Michigan, as well as an attending physician at the University of Michigan Health Systems and the VA Ann Arbor Healthcare System. Dr. Burns received his medical degree from Yale University School of Medicine and was awarded a research training fellowship by the Howard Hughes Medical Institute. He completed an internship and residency in general surgery at The Johns Hopkins Hospital followed by clinical fellowship training in complex general surgical oncology at The University of Texas MD Anderson Cancer Center. Additionally, he completed postgraduate research fellowships in the field of cancer immunotherapy and tumor immunology at the National Cancer Institute and the MD Anderson Cancer Center. Dr. Burns specializes in treating patients with tumors of the pancreas and gastrointestinal tract, sarcoma and melanoma. He is trained in traditional and minimally invasive surgical techniques. Furthermore, he works closely with colleagues in medical and radiation oncology to provide comprehensive cancer care. His research focuses on immune cell-tumor cell interactions to improve outcomes in patients with pancreatic cancer, cancer immunotherapy for solid tumors, the role of lymph node surgery in the treatment of cancer, and human biospecimen analysis to guide therapy in patients with cancer. He is a member of several professional societies, including the American College of Surgeons, Society of Surgical Oncology, Association of Academic Surgery, and Society of Immunotherapy for Cancer. Dr. Burns is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Neuroendocrine Tumor, Familial Pancreatic Cancer, Familial Colorectal Cancer, Small Bowel Resection, and Pancreatectomy.

Gang Chen is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Chen is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Colorectal Cancer, Myelodysplastic Syndrome (MDS), Familial Colorectal Cancer, Paget Disease of the Breast, and Hepato-Pancreato-Biliary Surgery. Dr. Chen is currently accepting new patients.

Richard Schraeder is a Hematologist Oncology specialist and a Hematologist in Towson, Maryland. Dr. Schraeder is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Retroperitoneal Liposarcoma. Dr. Schraeder is currently accepting new patients.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

David J. Hackam, M.D., Ph.D., is the Garrett Family Professor of Pediatric Surgery at The Johns Hopkins University, and Pediatric Surgeon-in-Chief and co-Director of the Johns Hopkins Children’s Center. Dr. Hackam’s clinical practice focuses on complex neonatal surgery. As pediatric surgeon in chief and co-director of the Childrens Center, Dr. Hackam oversees all perioperative clinical operations that involve children, with a strong emphasis on quality and safety, programmatic growth, and system alignment. Dr. Hackam's research is focused on unraveling the mechanisms of necrotizing enterocolitis, which is the leading cause of death in premature infants from gastrointestinal disease. His work has identified a series of novel pathways that, in response to the abnormal microflora that characterizes the premature intestine, leads to intestinal mucosal barrier breakdown, bacterial translocation, mesenteric vasoconstriction, and NEC. In seeking to translate these findings to clinical studies, we have developed a family of molecules that can prevent NEC development, and which have in part been licensed for clinical development. In additional work, Hackam has developed a prototype artificial intestine, derived from patient-specific intestine stem cells, which we have implanted into pre-clinical models, for the treatment of short bowel syndrome, a devastating complication of NEC. Finally, using single-cell RNA-seq and cell tracking technology, Hackam has worked towards understanding and treating NEC-associated brain injury, a major complication of NEC, and has engineered nanoparticle-packaged molecules that can cross the blood-brain barrier, and reverse the processes that lead to this disease. These studies are funded by three ro1s, a T32, a MIRA (a maximizing investigators’ research award) and 3 industry grants from companies with an interest in NEC treatment and prevention. Dr. Hackam seeks to work with industry partners, as well as nurses, doctors, and families of patients around the country, in order to develop novel regimens to safely and effectively deliver appropriate nutrition to the most vulnerable infants, who are at risk for the development of intestinal disease. Dr. Hackam is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Necrotizing Enterocolitis, Necrosis, Short Bowel Syndrome, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Ilene S. Browner, M.D. specializes in geriatric oncology. Dr. Browner is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Endoscopy.

Kelly Lafaro, MD, MPH, is a general surgeon with a specialty in gastrointestinal surgical oncology and hepatobiliary surgery. She is part of the Johns Hopkins Kimmel Cancer Center. Dr. Lafaro earned her medical degree from Tulane University School of Medicine and completed her residency at New York-Presbyterian/Columbia University Irving Medical Center. Her fellowship in complex general surgical oncology was completed at City of Hope National Medical Center. Dr. Lafaro’s expertise includes pancreatic adenocarcinoma, neuroendocrine tumors, minimally invasive pancreatic and liver surgeries, and colorectal liver metastases. In addition to her clinical experience, Dr. Lafaro is published in the field of liver and pancreatic cancer. She is interested in the improvement of surgical and post-surgical outcomes. Dr. Lafaro is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreatectomy, and Pancreaticoduodenectomy.

As an Associate Professor and Director of the Gastrointestinal Program in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins School of Medicine, Dr. Meyer's clinical and research focus is on the treatment of gastrointestinal cancers, including rectal, anal, esophageal, pancreatic, and liver malignancies. He is also leading the effort to establish a liver stereotactic body radiation therapy (SBRT) program within the department. Dr. Meyer has experience with clinical research studies in SBRT, as well as radiation and drug combination therapy for cancer. Make A Gift. Dr. Meyer is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.